BioE, Inc.

Development of human stem cells and antibody-based technologies

BioE, Inc. was founded as a privately owned company in 1993.

BioE is particularly focused on stem cell research across different fields including regenerative medicine and drug development.

Currently, BioE makes clonal adult-source stem cell lines available for application.

Michael Haider, President and CEO
Daniel Collins, Ph.D., CSO
Carol Buchert, MT(ASCP), VP of Operations and Sales/Marketing
Sarah A E Haecker, Ph.D., VP-Corporate Development
Timothy McGrath, VP-Finace and Accounting
Gayl Rogers Chrysler, VP-Cellular Technologies and Clinical Affairs

4280 Centerville Road
St. Paul, MN 55127
USA
Phone: +1-800-350-6466
Fax: +1-651-287-0354

The company’s first commercial stem cell product, known under the name of Multi-Lineage Progenitor Cells™ (MLPCs™), consists of human stem cells derived from umbilical cord blood. These multipotent stem cells can differentiate into bone cells, skeletal muscle, fat cells, blood vessels, nerve cells and liver/pancreas precursors.

In addition, BioE has developed a cell separation technology (PrepaCyte®) which enables the extraction of MLPCs™ from umbilical cord blood as well as the isolation of stem cells and T-cells from adult blood sources.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.